

**GUIDELINE 7.06: COMPLEMENTARY MEDICINES  
GUIDANCE ON SPECIFIED SUBSTANCES**

**To all stakeholders**

The purpose of Guideline 7.06 (Complementary Medicines – Guidance on specified substances) is to provide guidance to applicants on the use of specified substances in Complementary Medicines and their further application for registration.

Following the amendments to the Schedules as published on the 22 May 2020, SAHPRA developed guidance on the use of Cannabidiol as a specified substance used in Complementary Medicines and list Cannabidiol in annexures to Guideline 7.06 bearing in mind any limitations imposed by the Schedule inscription for CBD.

In assessing the safety, efficacy and quality of Cannabidiol (CBD) the attached Annexure 4 has been developed to guide the use of the substances listed therein when used in Complementary Medicines as Health Supplements. The attached Annexure 4: Cannabidiol (CBD) to the Guideline 7.06 is now published for implementation following SAHPRA's review of comments received.



**DR B SEMETE-MAKOKOTLELA**

**CHIEF EXECUTIVE OFFICER: SAHPRA**